Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Gyre Therapeutics (GYRE) over the last 15 years, with Q3 2025 value amounting to $58000.0.

  • Gyre Therapeutics' Current Deferred Revenue rose 6111.11% to $58000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $58000.0, marking a year-over-year increase of 6111.11%. This contributed to the annual value of $61000.0 for FY2024, which is 5641.03% up from last year.
  • Gyre Therapeutics' Current Deferred Revenue amounted to $58000.0 in Q3 2025, which was up 6111.11% from $28000.0 recorded in Q1 2025.
  • In the past 5 years, Gyre Therapeutics' Current Deferred Revenue ranged from a high of $2.0 million in Q2 2021 and a low of $28000.0 during Q1 2025
  • Moreover, its 5-year median value for Current Deferred Revenue was $59500.0 (2024), whereas its average is $409333.3.
  • The largest annual percentage gain for Gyre Therapeutics' Current Deferred Revenue in the last 5 years was 51757.58% (2021), contrasted with its biggest fall of 8840.14% (2021).
  • Gyre Therapeutics' Current Deferred Revenue (Quarter) stood at $230000.0 in 2021, then tumbled by 36.96% to $145000.0 in 2022, then crashed by 73.1% to $39000.0 in 2023, then soared by 56.41% to $61000.0 in 2024, then fell by 4.92% to $58000.0 in 2025.
  • Its last three reported values are $58000.0 in Q3 2025, $28000.0 for Q1 2025, and $61000.0 during Q4 2024.